Lantheus

LNTH

Market cap $4.35B

BEDFORD, Mass., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians Find, Fight, and Follow disease to deliver better patient outcomes, today announced it has completed the previously announced sale of its single photon emission computed tomography (SPECT) business to SHINE Technologies, LLC, a subsidiary of Illuminated Holdings, Inc. (collectively, “SHINE”). Under the terms of the agreement, SHINE has acquired Lantheus' SPECT business, including its diagnostic agents (TechneLite® (Technetium Tc 99m generator), NEUROLITE® (Kit for the Preparation of Technetium Tc 99m Bicisate for Injection), Xenon Xe-133 Gas (Xenon Xe-133 Gas), and Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection)), the portion of the North Billerica, Massachusetts campus that manufactures Lantheus' SPECT products, and the SPECT-related Canadian operations.

New York City-based Nitorum Capital sold 344,444 shares of Lantheus Holdings in the third quarter. The net position change was approximately $28.2 million from the previous period.

New York City-based Brigade Capital Management increased its LNTH holding by 173,200 shares in the third quarter. The move contributed to a net position value increase of about $4.51 million.

Philadelphia, Pennsylvania--(Newsfile Corp. - December 7, 2025) - Grabar Law Office is investigating claims on behalf of shareholders of Lantheus Holdings, Inc. (NASDAQ: LNTH). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

Lantheus Holdings offers compelling value as a leading cancer diagnostic and treatment company, with a robust drug pipeline and defensive business model. LNTH shares have dropped nearly 60% since March due to weaker sales, product pricing issues, and rising costs, compressing margins in 2025. Despite recent challenges (or because of), Lantheus trades at a historically low valuation, with analysts forecasting improved earnings over the next 12-18 months.

Small-cap stocks extended their momentum into the third quarter. We believe Rambus' evolution from a licensing and patent company into a full-fledged product company is progressing well. Shake Shack stock pulled back following quarterly results that did not meet elevated expectations.

NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Lantheus Holdings, Inc. (NASDAQ: LNTH).

LOS ANGELES, Nov. 10, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Lantheus Holdings, Inc., (“Lantheus” or the "Company") (NASDAQ: LNTH) investors of a class action on behalf of investors that bought securities between February 26, 2025 and August 5, 2025, inclusive (the “Class Period”). Lantheus investors have until November 10, 2025 to file a lead plaintiff motion.

NEW YORK--(BUSINESS WIRE)---- $LNTH #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH) and reminds investors of the November 10, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

LOS ANGELES, Nov. 10, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lantheus Holdings, Inc. (“Lantheus” or “the Company”) (NASDAQ: LNTH) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 26, 2025, and August 5, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before November 10, 2025.